> Voriconazole should be administered with caution in patients with concomitant medication that is known to prolong QTc interval. When there is also a potential for voriconazole to increase the plasma concentrations of substances metabolised  by CYP3A4 isoenzymes (certain antihistamines, QUINIDINE, CISAPRIDE, PIMOZIDE  and IVABRADINE ), coadministration is contraindicated (see below and section  4.3).
> Medicinal product  
[Mechanism of interaction]  Interaction  Geometric mean changes (%) Recommendations  concerning  coadministration  ASTEMIZOLE, CISAPRIDE,  PIMOZIDE, QUINIDINE  TERFENADINE  and IVABRADINE  
[CYP3A4 substrates]  Although not studied, increased plasma concentrations of these medicinal products can lead to QTc prolongation and rare occurrences of torsades de pointes  Contraindicated  (see section  4.3) CARBAMAZEPINE and long -acting barbiturates (e.g., PHENOBARBITAL,  mephobarbital)  
[potent CYP450 inducers]  Although not studied, CARBAMAZEPINE and long -acting barbiturates are likely to significantly decrease plasma voriconazole concentrations.  Contraindicated  (see section  4.3) EFAVIRENZ (a non -nucleoside  reverse transcriptase inhibitor)  
[CYP450 inducer; CYP3A4  inhibitor and substrate] 
> Use of standard doses of voriconazole with EFAVIRENZ doses of  
400 mg QD or higher is contraindicated (see section  4.3).
> Voriconazole may be coadministered with EFAVIRENZ if the voriconazole maintenance dose is increased to 
400 mg BID and the EFAVIRENZ dose is decreased to 300  mg QD.  When voriconazole treatment is stopped, the initial dose of EFAVIRENZ should be restored (see section  4.2 and 4.4). ERGOT ALKALOIDS (e.g.,  ERGOTAMINE and DIHYDROERGOTAMINE)  Although not studied, voriconazole is likely to increase the plasma Contraindicated (see section  4.3) 12  [CYP3A4 substrates]  concentrations of ERGOT ALKALOIDS and lead to ergotism.  LURASIDONE  
[CYP3A4 substrate] 
> Although not studied,  voriconazole is likely to significantly increase the plasma concentrations of LURASIDONE.  Contraindicated  (see section 4.3)  Naloxegol  
[CYP3A4 substrate]  Although not studied, voriconazole is likely to significantly increase the plasma concentrations of naloxegol.  Contraindicated  (see section 4.3)  RIFABUTIN  
[potent CYP450 inducer] 
> Compared to voriconazole 200 mg BID,  Voriconazole C max   104%  Voriconazole AUCτ   87% Concomitant use of  voriconazole and RIFABUTIN  should be avoided unless the  benefit outweighs the risk. The maintenance dose of  voriconazole may be increased  to 5 mg/kg intravenously BID  or from 200 mg to 350 mg  orally BID (100 mg to 200 mg  orally BID in patients less than  
40 kg) (see section  4.2). Careful monitoring of full  blood counts and adverse  reactions to RIFABUTIN (e.g.,  uveitis) is recommended when  RIFABUTIN is coadministered  with voriconazole.  Rifampicin (600 mg QD)  
[potent CYP450 inducer]  Voriconazole C max   93% Voriconazole AUCτ   96% Contraindicated (see section  4.3) RITONAVIR (protea se inhibitor)  
[potent CYP450 inducer;  CYP3A4 inhibitor and  substrate] 
> St John’s Wort  
[CYP450 inducer; P -gp inducer]  
300 mg TID (coadministered  with voriconazole 400 mg  single dose)   In an independent published study,  Voriconazole AUC 0-∞  59% Contraindicated (see section  4.3) TOLVAPTAN  
[CYP3A substrate ] Although not studied, voriconazole is likely to significantly increase the Contraindicated  (see section 4.3)  13  plasma concentrations of TOLVAPTAN.  VENETOCLAX  
[CYP3A substrate]  Although not studied, voriconazole is likely to significantly increase the plasma concentrations of VENETOCLAX.  Concomitant administration of voriconazole is contraindicated  at initiation and during VENETOCLAX dose titration phase (see section 4 .3). Dose reduction of VENETOCLAX is required as instructed in VENETOCLAX prescribing information during steady daily dosing; close monitoring for signs of toxicity is recommended. 
> Concomitant use of voriconazole and PHENYTOIN should be avoided unless the benefit outweighs the risk. Careful monitoring of PHENYTOIN plasma levels is recommended. 
> PHENYTOIN may be co -administered with voriconazole if the maintenance dose of voriconazole is increased to 
5 mg/kg IV BID or from 200  mg to 
400 mg oral BID, (100 mg to 200  mg oral BID in patients less than 40  kg) (see section  4.2). LETERMOVIR  
[CYP2C9 and  CYP2C19 inducer ] Voriconazole Cmax ↓ 39%  Voriconazole AUC0 -12 ↓ 44%  Voriconazole C12  ↓ 51%  If concomitant administration of voriconazole with LETERMOVIR cannot be avoided, monitor for loss of voriconazole effectiveness.  GLASDEGIB  
[CYP3A4 substrate]  Although not studied, voriconazole is likely to increase the plasma concentrations of GLASDEGIB and increase risk of QTc prolongation.  If concomitant use cannot be avoided, frequent ECG moni toring is recommended  (see section 4. 4). Tyrosine kinase inhibitors (e.g., AXITINIB, BOSUTINIB, CABOZANTINIB, CERITINIB, COBIMETINIB, DABRAFENIB, DASATINIB, NILOTINIB, SUNITINIB, IBRUTINIB, RIBOCICLIB)  Although not studied, voriconazole may increase plasma concentrations of tyrosine kinase inhibitors metaboli sed by CYP3A4 . If concomitant use cannot be avoided, dose reduction of the tyrosine kinase inhibitor is recommended  (see section 4 .4). 14  [CYP3A4 substrates]  Anticoagulants 
> Close monitoring of  prothrombin time or other  suitable anticoagulation tests is  recommended and the dose of  anticoagulants should be  adjusted  accordingly.  IVACAFTOR  
[CYP3A4 substrate]  Although not studied, voriconazole is likely to increase the plasma concentrations of IVACAFTOR with risk of increased adverse reactions . Dose reduction of IVACAFTOR is recommended.  Benzodiazepines [CYP3A4 substrates]  MIDAZOLAM (0.05 mg/kg IV single dose) 
> 
 Although not studied, voriconazole is likely to significantly increase the plasma concentrations of EVEROLIMUS. 
> 
 Coadministration of voriconazole and EVEROLIMUS is not recommended because voriconazole is expected to significantly increase EVEROLIMUS concentrations (see section 4.4). 
> 
 TACROLIMUS C max  117%  TACROLIMUS AUC t  221%  in patients already on  CICLOSPORIN it is recommended  that the CICLOSPORIN dose be  halved and CICLOSPORIN level  carefully monitored. Increased  CICLOSPORIN levels have been  associated with nephrotoxicity.  When voriconazole is  discontinued, CICLOSPORIN  levels must be carefully  monitored and the dose  increased as necessary. 
> When initiating voriconazole  in patients already on  TACROLIMUS, it is recommended  that the TACROLIMUS dose be  reduced to a third of the  original dose and TACROLIMUS  level carefully monitored.  Increased TACROLIMUS levels  have been associated with nephrotoxicity. When  voriconazole is discontinued,  TACROLIMUS levels must be  carefully monitored and the  dose increased as necessary.  Long -Acting Opiates  
[CYP3A4 substrates] 
> When initiating voriconazole  16  Other PROTON PUMP INHIBITORS that are CYP2C19 substrates may also be inhibited by voriconazole and may result in increased plasma concentrations of thes e medicinal products.  in patients already receiving  OMEPRAZOLE doses of 40  mg or  above, it is recommended that  the OMEPRAZOLE dose be halved.  Oral Contraceptives*  
[CYP3A4 s ubstrate; CYP2C19  inhibitor]  Norethisterone/ethinylestradiol (1 mg/0.035  mg QD)  Ethinylestradiol C max  36% Ethinylestradiol AUCτ  61% Norethisterone C max  15% Norethisterone AUCτ   53% Voriconazole C max  14% Voriconazole AUCτ  46% Monitoring for adverse  reactions related to oral  contraceptives, in addition to  those for voriconazole, is  recommended  Short -acting Opiates  
[CYP3A4 substrates] 
> ALFENTANIL (20 μg/kg single  dose, with concomitant  NALOXONE) 
> 
 In an independent published study,  FENTANYL AUC 0-∞  1.34-fold Dose reduction of ALFENTANIL,  FENTANYL and other short -acting  opiates similar in structure to  ALFENTANIL and metabolised by  CYP3A4 (e .g., SUFENTANIL)  should be considered.  Extended and frequent  monitoring for respiratory  depression and other opiate associated adverse reactions is  recommended.  Statins (e.g., LOVASTATIN)  
[CYP3A4 substrates]  Although not studied, voriconazole is likely to  increase the plasma concentrations of statins that are metabolised by CYP3A4 and could lead to rhabdomyolysis.  If concomitant administration of voriconazole with statins metabolised by CYP3A4 cannot be avoided, dose reduction of the statin  should be consi dered.  SULFONYLUREAS (e.g.,  TOLBUTAMIDE, GLIPIZIDE,  GLYBURIDE)  
[CYP2C9 substrates]  Although not studied, voriconazole is likely to increase the plasma concentrations of SULFONYLUREAS and cause hypoglycaemia.  Careful monitoring of blood  GLUCOSE is recommen ded. Dose  reduction of SULFONYLUREAS  should be considered  Vinca Alkaloids (e.g.,  VINCRISTINE and VINBLASTINE)  
[CYP3A4 substrates]  Although not studied, voriconazole is likely to increase the plasma concentrations of vinca alkaloids and lead to neurotoxicity.  Dose reduction of vinca  alkaloids should be considered.  Other HIV PROTEASE INHIBITORS  (e.g., SAQUINAVIR, AMPRENAVIR  and NELFINAVIR)*  
[CYP3A4 substrates and  inhibitors]  Not studied clinically. In vitro  studies show that voriconazole may inhi bit the metabolism of HIV PROTEASE INHIBITORS and the metabolism of voriconazole may also be inhibited by HIV PROTEASE INHIBITORS.  Careful monitoring for any  occurrence of drug toxicity  and/or lack of efficacy, and  dose adjustment may be needed.  Other Non -Nucleoside Reverse  Transcriptase Inhibitors  (NNRTIs) (e.g., DELAVIRDINE,  NEVIRAPINE)*  Not studied clinically. In vitro  studies show that the metabolism of voriconazole may be inhibited by NNRTIs and voriconazole may inhibit Careful monitoring for any  occurrence of drug toxicity  and/or lack of efficacy , and  dose adjustment may be  needed.  17  [CYP3A4 substrates, inhibitors  or CYP450 inducers]  the metabolism of NNRTIs. The findings of the effect of EFAVIRENZ on voriconazole suggest that the metabolism of voriconazole may be induced by an NNRTI  TRETINOIN  
[CYP3A4 substrate]  Although not studied, voriconazole may increase TRETINOIN concentrations and increase risk of adverse  reactions  (pseudotumor cerebri, hypercalcaemia) . Dose adjustment of TRETINOIN is recommended during treatment with voriconazole and after its discontinuation.  CIMETIDINE (400 mg BID)  
[non -specific CYP450 inhibitor and increases gastric p
> Patients on long -term treatment with voriconazole and CORTICOSTEROIDS (including inhaled CORTICOSTEROIDS e.g., BUDESONIDE and intranasal CORTICOSTEROIDS) should be carefully monitored for adrenal cortex dysfunction both during treatment and when voriconazo le is discontinued (see section 4.4).  RANITIDINE (150  mg BID)  
[increases gastric p
> H]  Voriconazole C max and AUCτ 
↔ No dose adjustment  FLUCLOXACILLIN [CYP450 inducer]  Significantly decreased plasma voriconazole If concomitant administration of voriconazole with FLUCLOXACILLIN cannot be avoided, monitor for 18  concentrations have been reported.  potential loss of voriconazole effectiveness (e.g. by therapeutic drug monitoring); increasing the dose of voriconazole may be needed 
